The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
Open accessAbstract
Human monocyte-derived DCs (moDCs) and circulating conventional DCs coexpress activating (CD32a) and inhibitory (CD32b) isoforms of IgG Fcgamma receptor (FcgammaR) II (CD32). The balance between these divergent receptors establishes a threshold of DC activation and enables immune complexes to mediate opposing effects on DC maturation and function. IFN-gamma most potently favors CD32a expression on immature DCs, whereas soluble antiinflammatory concentrations of monomeric IgG have the opposite effect. Ligation of CD32a leads to DC maturation, increased stimulation of allogeneic T cells, and enhanced secretion of inflammatory cytokines, with the exception of IL-12p70. Coligation of CD32b limits activation through CD32a and hence reduces the immunogenicity of moDCs even for a strong stimulus like alloantigen. Targeting CD32b alone does not mature or activate DCs but rather maintains an immature state. Coexpression of activating and inhibitory FcgammaRs by DCs reveals a homeostatic checkpoint for inducing tolerance or immunity by immune complexes. These findings have important implications for understanding the pathophysiology of immune complex diseases and for optimizing the efficacy of therapeutic mAbs. The data also suggest novel strategies for targeting antigens to the activating or inhibitory FcgammaRs on human DCs to generate either antigen-specific immunity or tolerance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sallusto, F., & Lanzavecchia, A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.4.1109 · Cited by 5,129
Blood Monocytes Consist of Two Principal Subsets with Distinct Migratory Properties
Geissmann, F., Jung, S., & Littman, D. R. (2003) · Immunity · doi:10.1016/s1074-7613(03)00174-2 · Cited by 3,391
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood
Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.284.5421.1835 · Cited by 2,293
Mellman, I., & Steinman, R. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00449-4 · Cited by 2,237
Ravetch, J. V., & Bolland, S. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.275 · Cited by 1,657
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Dzionek, A., Fuchs, A., Schmidt, P., Cremer, S., Zysk, M., Miltenyi, S., Buck, D. W., & Schmitz, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6037 · Cited by 1,298
Ravetch, J. V., & Lanier, L. L. (2000) · Science · doi:10.1126/science.290.5489.84 · Cited by 1,283
Grouard, G., Rissoan, M.-C., Filgueira, L., Durand, I., Banchereau, J., & Liu, Y.-J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.6.1101 · Cited by 1,189
Jonuleit, H., Kühn, U., Müller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J., & Enk, A. H. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271209 · Cited by 1,163
Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor
Samuelsson, A., Towers, T. L., & Ravetch, J. V. (2001) · Science · doi:10.1126/science.291.5503.484 · Cited by 1,053
Identification and characterization of a novel monocyte subpopulation in human peripheral blood
Passlick, B., Flieger, D., & Ziegler-Heitbrock, H. (1989) · Blood · doi:10.1182/blood.v74.7.2527.2527 · Cited by 1,037
Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Théry, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.371 · Cited by 898
Spontaneous Autoimmune Disease in FcγRIIB-Deficient Mice Results from Strain-Specific Epistasis
Bolland, S., & Ravetch, J. V. (2000) · Immunity · doi:10.1016/s1074-7613(00)00027-3 · Cited by 752
Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily.
Zhou, L. J., & Tedder, T. F. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.8.3821 · Cited by 736
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
Immunotherapy: past, present and future
Waldmann, T. A. (2003) · Nature Medicine · doi:10.1038/nm0303-269 · Cited by 628
Charles, P. J., Elliott, M. J., Davis, D., Potter, A. R., Kalden, J. R., Antoni, C., Breedveld, F. C., Js, S., Eberl, G., DeWoody, K. L., et al. (1999) · PubMed · Cited by 531
Thurner, B., Röder, C., Dieckmann, D., Heuer, M., Kruse, M., Glaser, A., Keikavoussi, P., Kämpgen, E., Bender, A., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00208-7 · Cited by 482
Cytoplasmic Domain Heterogeneity and Functions of IgG Fc Receptors in B Lymphocytes
Amigorena, S., Bonnerot, C., Drake, J. R., Choquet, D., Hunziker, W., Guillet, J.-G., Webster, P., Sautes, C., Mellman, I., & Fridman, W. H. (1992) · Science · doi:10.1126/science.1535455 · Cited by 455
de Saint-Vis, B., Vincent, J., Vandenabeele, S., Vanbervliet, B., Pin, J.-J., Aït-Yahia, S., Patel, S., Mattei, M.-G., Banchereau, J., Zurawski, S., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80615-9 · Cited by 399
Kalergis, A. M., & Ravetch, J. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020338 · Cited by 372
Dhodapkar, K. M., Krasovsky, J., Williamson, B., & Dhodapkar, M. V. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011097 · Cited by 349
Parren, P. W., Warmerdam, P. A., Boeije, L. C., Arts, J., Westerdaal, N. A., Vlug, A., Capel, P. J., Aarden, L. A., & van de Winkel, J. G. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116022 · Cited by 346
Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells
Tax, W. J. M., Willems, H. W., Reekers, P. P. M., Capel, P. J. A., & Koene, R. A. P. (1983) · Nature · doi:10.1038/304445a0 · Cited by 327
Molecular basis for a polymorphism of human Fc gamma receptor II (CD32).
Warmerdam, P. A., van de Winkel, J. G., Gosselin, E. J., & Capel, P. J. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.1.19 · Cited by 298
FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy
Van Sorge, N. M., Van Der Pol, W., & Van De Winkel, J. G. J. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00037.x · Cited by 294
Dendritic Cells Enhance Growth and Differentiation of CD40-activated B Lymphocytes
Dubois, B., Vanbervliet, B., Fayette, J., Massacrier, C., Kooten, C. V., Brière, F., Banchereau, J., & Caux, C. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.5.941 · Cited by 291
Restoration of Tolerance in Lupus by Targeted Inhibitory Receptor Expression
McGaha, T. L., Sorrentino, B., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1105160 · Cited by 261
Dhodapkar, K. M., Kaufman, J. L., Ehlers, M., Banerjee, D. K., Bonvini, E., Koenig, S., Steinman, R. M., Ravetch, J. V., & Dhodapkar, M. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500014102 · Cited by 241
Type I (CD64) and type II (CD32) Fc γ receptor-mediated phagocytosis by human blood dendritic cells
Fanger, N. A., Wardwell, K., Shen, L., Tedder, T. F., & Guyre, P. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.2.541 · Cited by 236
FcγRIIb Balances Efficient Pathogen Clearance and the Cytokine-mediated Consequences of Sepsis
Clatworthy, M. R., & Smith, K. G. C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20032197 · Cited by 139
Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects
Rose, A. L., Smith, B. E., & Maloney, D. G. (2002) · Blood · doi:10.1182/blood.v100.5.1765.h81702001765_1765_1773 · Cited by 129
Fcγ Receptors and Cross-Presentation in Dendritic Cells
Amigorena, S. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011925 · Cited by 129
Fcγ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura
Carcao, M. D., Blanchette, V. S., Wakefield, C. D., Stephens, D., Ellis, J., Matheson, K. A., & Denomme, G. A. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04033.x · Cited by 89
Armour, K. L., van de Winkel, J. G. J., Williamson, L. M., & Clark, M. (2003) · Molecular Immunology · doi:10.1016/j.molimm.2003.08.004 · Cited by 74
Immune complexes are potent inhibitors of interleukin‐12 secretion by human monocytes
Berger, S., Chandra, R., Balló, H., Hildenbrand, R., & Stutte, H. J. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271136 · Cited by 68
Bánki, Z., Kacani, L., Müllauer, B., Wilflingseder, D., Obermoser, G., Niederegger, H., Schennach, H., Sprinzl, G. M., Sepp, N. T., Erdei, A., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.8.3963 · Cited by 61
Radstake, T. R. D. J., van Lent, P. L. E. M., Pesman, G. J., Blom, A. B., Sweep, F. C. G. J., Rönnelid, J., Adema, G. J., Barrera, P., & van den Berg, W. B. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.010033 · Cited by 54
Maresco-Pennisi, D. L., Osborne, J. M., Cooney, D. S., Coggeshall, K. M., & Anderson, C. L. (1999) · PubMed · Cited by 52
Vely, F., Gruel, N., Moncuit, J., COCHET, O., Rouard, H., Daré, S., Galon, J., Sautès‐Fridman, C., Fridman, W. H., & Teillaud, J. (1997) · Hybridoma · doi:10.1089/hyb.1997.16.519 · Cited by 39
Cited by
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Fcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Type I Interferon in Systemic Lupus Erythematosus and Other Autoimmune Diseases
Banchereau, J., & Pascual, V. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.010 · Cited by 963
Metadata
- Authors
- Boruchov, A. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-10-01
- Volume
- 115
- Issue
- 10
- Pages
- 2914-2923
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2097690601
- Cited by
- 377
- References
- 43
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.